SCHEMBL17376184

SCHEMBL17376184

COc1cc(-c2ccccc2OC)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVR2A P27037 7/20 0.49
TGFBR2 P37173 7/20 0.49
IDO1 P14902 1/20 0.49
PDGFRB P09619 1/20 0.49
PDGFRA P16234 1/20 0.49
PTPRC P08575 1/20 0.49
PTPN1 P18031 1/20 0.49
MAP4K4 O95819 1/20 0.48
DYRK1A Q13627 1/20 0.47
MAPK10 P53779 1/20 0.46
TGFBR1 P36897 1/20 0.46
CYP1A2 P05177 3/20 0.46
CYP3A4 P08684 3/20 0.46
CYP2D6 P10635 3/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46
CYP2C19 P33261 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL744054 0.84 IDO1 (0.50) ACVR2ATGFBR2IDO1DYRK1ATGFBR1
SCHEMBL11919644 0.83 WNT3A (0.54) PDGFRBPDGFRAPTPRCPTPN1MAP4K4
SCHEMBL22283951 0.81 IDO1 (0.48) ACVR2ATGFBR2IDO1DYRK1ATGFBR1
SCHEMBL30042559 0.81 IDO1 (0.48) ACVR2ATGFBR2IDO1DYRK1ATGFBR1
SCHEMBL12268828 0.81 RORB (0.56) PDGFRBPDGFRAPTPRCPTPN1MAP4K4
SCHEMBL12486954 0.81 ALOX5AP (0.49) PDGFRBPDGFRAPTPRCPTPN1MAP4K4
SCHEMBL3361169 0.81 DYRK1A (0.60) PDGFRBPDGFRAPTPRCPTPN1MAP4K4
SCHEMBL17376313 0.81 PDGFRB (0.48) PDGFRBPDGFRAPTPRCPTPN1MAP4K4
SCHEMBL30626327 0.79 LOX (0.55) ACVR2ATGFBR2IDO1DYRK1ATGFBR1
SCHEMBL16116782 0.79 LOX (0.55) ACVR2ATGFBR2IDO1DYRK1ATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11261164-B2 Small molecule agonists of neurotensin receptor 1 Sanford Burnham Prebys Medical Discovery Institute (US) 2022-03-01 US disclosed
US-20200354324-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2020-11-12 US disclosed
US-20200354324-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2020-11-12 US disclosed
US-10584103-B2 Small molecule agonists of neurotensin receptor 1 Sanford Burnham Prebys Medical Discovery Institute (US) 2020-03-10 US disclosed
US-20190023665-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 Sanford Burnham Prebys Medical Discovery Institute 2019-01-24 US disclosed
US-20190023665-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 Sanford Burnham Prebys Medical Discovery Institute 2019-01-24 US disclosed
US-10118902-B2 Small molecule agonists of neurotensin receptor 1 Sanford Burnham Prebys Medical Discovery Institute (US) 2018-11-06 US disclosed
US-20170240514-A1 Small Molecule Agonists of Neurotensin Receptor 1 Sanford Burnham Prebys Medical Discovery Institute 2017-08-24 US disclosed
US-20170240514-A1 Small Molecule Agonists of Neurotensin Receptor 1 Sanford Burnham Prebys Medical Discovery Institute 2017-08-24 US disclosed
US-20170240514-A1 Small Molecule Agonists of Neurotensin Receptor 1 Sanford Burnham Prebys Medical Discovery Institute 2017-08-24 US disclosed
EP-3160961-A2 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 Sanford-Burnham Medical Research Institute (US) 2017-05-03 EP disclosed
WO-2015200534-A2 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2015-12-30 WO disclosed
WO-2015200534-A2 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2015-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10584103-B2 Small molecule agonists of neurotensin receptor 1 NTSR1, NTSR2, VIPR1 ACVR2A 626/4885TGFBR2 1261/4885IDO1 2413/4885
US-11261164-B2 Small molecule agonists of neurotensin receptor 1 NTSR1, NTSR2, VIPR1 ACVR2A 626/4885TGFBR2 1261/4885IDO1 2413/4885
US-20170240514-A1 Small Molecule Agonists of Neurotensin Receptor 1 NTSR1, NTSR2, VIPR1 ACVR2A 626/4885TGFBR2 1261/4885IDO1 2413/4885
US-10118902-B2 Small molecule agonists of neurotensin receptor 1 NTSR1, NTSR2, VIPR1 ACVR2A 626/4885TGFBR2 1261/4885IDO1 2413/4885
US-20200354324-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 NTSR1, NTSR2, VIPR1 ACVR2A 626/4885TGFBR2 1261/4885IDO1 2413/4885
US-20190023665-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 NTSR1, NTSR2, VIPR1 ACVR2A 626/4885TGFBR2 1261/4885IDO1 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.